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Background: Pulmonary artery sarcoma (PAS) is a rare but aggressive malignancy that leads to heart failure and
death without treatment. Here we reviewed the presentation and management of patients treated at a national
centre for pulmonary endarterectomy (PEA) and its associated hospital in Cambridge, UK.
Methods: Details of PAS patients treated at Papworth and Addenbrooke’s Hospitals between 2000 and 2014 were
reviewed.
Results: Twenty patients were diagnosed with PAS (11 males, 9 females), with a median age of presentation of
57 years (range 27–77). Presenting symptoms include dyspnoea (20), chest pain/tightness (7), oedema (5), constitutional
symptoms (5), cough (3) and haemoptysis (3). Twelve patients were in group III/IV of the NYHA functional classification
of symptoms. Initial CT scans were suggestive of thromboembolism in seven patients. Histological findings were of
intimal sarcoma (13) and high grade sarcoma NOS (6).
Median overall survival (OS) was 17 months. Fourteen patients underwent PEA to relieve vascular obstruction, while six
had inoperable and/or metastatic disease. There were three peri-operative deaths. Although there was no difference in
median OS between patients who had PEA and those who did not (20 vs 17 months, P = 0.2488), surgery provided
significant symptomatic improvement and some with long-term survival. Five patients received post-surgical
chemotherapy (anthracycline +/− ifosfamide), and after completion four also had radiotherapy. Patients who received
post-operative chemo- and radio-therapy showed a trend towards better survival compared to those who had surgery
alone (24 vs 8 months, P = 0.3417). For palliative chemotherapy, partial responses were observed with the VID regimen
and pegylated liposomal doxorubicin. Stable disease was achieved in a patient with intimal sarcoma with
rhabdomyosarcomatous differentiation on third-line cisplatin and topotecan. The longest surviving patient (102 months)
has had PEA, adjuvant epirubicin and radiotherapy. She developed lung metastases 7 years later, which were treated
with radiofrequency ablation.
Conclusions: PAS often presents with symptoms mimicking pulmonary hypertension, heart failure or thromboembolic
disease. PEA provides good symptomatic relief and in some cases, offers a chance of long-term survival. Although
outcome appears to be better when PEA is combined with post-operative chemo- and radio-therapy, further studies
are warranted.
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Table 1 Patient characteristics (n = 20)
Variables No. of patients (%)
Gender
- Male 11 (55%)
- Female 9 (45%)
Median age (years) 57 (range 27 – 77)
- Male 64 (range 27 – 77)
- Female 57 (range 27 – 70)
Presenting symptoms
- Dyspnoea 20 (100%)
- Chest pain/tightness 7 (35%)
- Dependent oedema 5 (25%)
- Constitutional symptoms 5 (25%)
- Cough 3 (15%)
- Haemoptysis 3 (15%)
New York Heart Association functional classification
- I 0
- II 8 (40%)
- III 8 (40%)
- IV 4 (20%)
Clinical signs suggestive of pulmonary hypertension
- Present 16 (80%)
- Absent 4 (20%)
Pulmonary artery involvement
- Unilateral 3 (15%)
- Bilateral 17 (85%)
Disease stage
- Operable and non-metastatic 14 (70%)
- Inoperable and/or metastatic 6 (30%)
Histological subtype
- Intimal sarcoma 13 (65%)
- High-grade sarcoma NOS 6 (30%)
- Unable to obtain tissue for diagnosis 1 (5%)
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First described by Moritz Mandelstamm from an aut-
opsy in 1923, primary pulmonary artery sarcoma (PAS)
is an uncommon but increasingly recognised thoracic
malignancy, with only a few hundred cases reported in
the literature [1-3]. The aetiology is unknown and the
disease results in significant morbidity and high mortal-
ity. The clinical and radiological findings are often simi-
lar to those of thromboembolic disease, leading to delays
in confirming the diagnosis. Typically the disease pre-
sents in adulthood with symptoms including dyspnoea,
cough, haemoptysis, chest pain and weight loss.
Given the rarity of PAS only case reports and small
case series have been published, the majority focusing
on histopathological appearances and surgical aspects of
its management [2-12]. Surgery remains the mainstay of
management for patients with PAS, and can include pul-
monary endarterectomy (PEA), lobectomy and pneu-
monectomy [2,3,6]. The role of additional chemotherapy
and radiotherapy after surgical resection remains largely
unproven.
In this study, we report our experience in managing 20
patients with PAS over a period of 14 years at Papworth
Hospital, a national centre for PEA and its associated
Oncology Department at Addenbrooke’s Hospital in
Cambridge, UK. The 20 patients described in this report




Papworth Hospital in Cambridge, UK is a specialist car-
diothoracic centre. It is associated with Addenbrooke’s
Hospital which provides radiotherapy and systemic ther-
apy to the regional sarcoma population. Patients with
PAS treated at these two hospitals between the years of
2000 and 2014 were identified retrospectively. Diagnosis
was confirmed by histological examination and immuno-
histochemical staining. Patients’ clinical records were ob-
tained and examined. All 20 patients identified were
included in the study.
Statistical analysis
Survival analysis was performed using the Kaplan-Meier
method and log-rank test. Surviving patients were cen-
sored at last contact. A P value of <0.05 was considered
to be statistically significant.
Results
Patient characteristics
A total of 20 patients were treated at our centres be-
tween 2000 and 2014. The patient characteristics are
summarised in Table 1. Eleven (55%) patients were male
and the age at presentation ranged from 27 to 77 years,with a median of 57 years. The vast majority of patients
presented with symptoms consistent with acute or chronic
pulmonary hypertension such as dyspnoea (New York
Heart Association (NYHA) functional class III and IV in
60% of cases) and chest pain. Some experienced constitu-
tional symptoms of fever, night sweats, anorexia and
weight loss. Intimal sarcoma was the histological diagnosis
for the majority of the patients (65%), while high-grade
sarcoma NOS was found in 35%. We were unable to ob-
tain tumour tissue from an elderly patient with significant
co-morbidities despite radiologically-guided biopsy, al-
though his CT scan was unequivocal of PAS. In seven
(35%) of the total cases, initial CT images were suggestive
of pulmonary emboli (Figure 1).
Figure 1 Pulmonary artery intimal sarcoma mimicking pulmonary embolism. CT images of two patients who presented with dyspnoea and
dependent oedema.
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Table 2 summarises the treatments given. Fourteen (70%)
patients underwent PEA, while the remaining six (30%)
had inoperable (secondary to mediastinal invasion or ex-
tension into lung parenchyma) and/or metastatic disease.
PEA (Figure 2) is a high-risk procedure involving cardio-
pulmonary bypass and circulatory arrest under deep
hypothermia (18–20°C). There were three peri-operative
deaths (two of which had emergency surgery due to rapid
cardiovascular and respiratory deterioration but died on
the same day). However, the 11 patients who underwent
and survived PEA reported significant improvements in
their symptoms (all had post-operative NYHA score of I/
II). Immediate post-operative morbidities included atrial
fibrillation, chest infection, headache of uncertain aeti-
ology, and haemothorax that resolved after drainage. The
median length of hospital stay was 18 days (range 10 to
21 days). All resections were of R1 or R2.
Five patients received post-operative chemotherapy
(Table 3) – four of them had small volume metastases
and the other had no macroscopic residual disease. The
agents used were epirubicin, doxorubicin and/or ifosfa-
mide. Three patients received post-operative anthracy-
clines which they tolerated without clinical cardiotoxicity.
After chemotherapy, four patients also received immediate
radiotherapy – of these, three patients had metastatic lung
nodules and were given palliative doses of 30–36 Gy using
parallel opposed fields to the primary sites for local con-
trol. The remaining patient, who showed no evidence ofTable 2 Treatment modality (n = 20)
Variables No. of patients
Operable and non-metastatic disease
- Pulmonary endarterectomy 14
- Post-operative chemotherapy 5
- Post-operative radiotherapy 4
Inoperable, metastatic or recurrent disease
- Chemotherapy 5
- Radiotherapy 5
- Radiofrequency ablation 1disease after PEA and adjuvant epirubicin, was given a
radical dose of 60 Gy in 30 fractions by three-dimensional
conformal radiotherapy.
Patients with inoperable and/or metastatic disease
showed benefit from radiotherapy for locoregional con-
trol – four patients had disease stabilisation and one
demonstrated tumour shrinkage when it was combined
with chemotherapy. For those patients treated with pal-
liative chemotherapy, partial responses were observed
with vincristine, ifosfamide and doxorubicin (VID), and
pegylated liposomal doxorubicin hydrochloride (PLDH)
(Figure 3), although the time to progression was only 6
and 5 months, respectively. In two patients anthracycline-
based chemotherapy could not be given as a first-line
treatment secondary to cardiac dysfunction; one of the
two received single-agent paclitaxel but had to stop treat-
ment due to significant neutropaenia after only one dose
(Table 3). Stable disease that lasted 3 months was
achieved in a patient with intimal sarcoma with rhabdo-
myosarcomatous differentiation using third-line cisplatin
and topotecan.
Of the 20 patients with PAS, six received post-operative
or palliative therapy at our centre. The remaining 11 pa-
tients (after excluding three peri-operative deaths) re-
ceived their oncological treatments back at their referring
hospitals. Although we were able to access the majority of
the data, we could not obtain the complete information
for six patients – one patient was discharged back to her
local hospital after PEA but her post-operative treatment
is unknown; one patient with inoperable and metastatic
disease was transferred back to her referring hospital for
palliative treatment but the details are lacking; two pa-
tients received palliative radiotherapy for recurrence but
we cannot be certain whether they also had chemotherapy;
and we do not have the chemo- and radio-therapy details
of two patients who were treated for disease relapse.
Survival
The median overall survival (OS) for all 20 patients was
17 months (Figure 4). There was no difference in median
OS between patients who underwent PEA and those
who did not (20 vs 17 months, P = 0.2488), although
Figure 2 Pulmonary endarterectomy for pulmonary artery sarcoma. (a) CT image and resected specimen of a diffuse, bilateral pulmonary
artery sarcoma. (b) CT image and resected specimen of a saddle-type pulmonary artery sarcoma. (c) Resected specimen of a left-sided, intraluminal
pulmonary artery sarcoma.
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dynamic improvements, as well as some with long-term
survival. A trend towards better OS was demonstrated
for those who received both post-operative chemo- and
radio-therapy compared to those who did not, with OS
of 24 and 8 months, respectively (P = 0.3417).
Exceptional survivors
The longest surviving patient (102 months) is a 70-year-
old woman who presented with dyspnoea (NYHA class
III) and dependent oedema. She underwent PEA for a
saddle-type intimal sarcoma (R1 resection) and had no
radiological evidence of metastasis. Given the high prob-
ability of cancer dissemination secondary to the vascular
nature of the disease and surgical procedure, it was
decided that she would benefit from adjuvant chemo-
therapy followed by radiotherapy. She was given epirubi-
cin and a radical dose of radiotherapy (60 Gy in 30
fractions). She did not show any evidence of disease on
follow-up CT scans until 7 years later, when she devel-
oped lung metastases. These were treated with radiofre-
quency ablation. Although the disease in her lungs hasprogressed since then, these remain of small volume and
she is currently being kept under observation.
The second longest surviving patient (85 months) is a
57-year-old woman who presented with chest pain and
breathlessness (NYHA class II). CT scan showed a large
filling defect (maximum diameter of 4 cm) within the
right main pulmonary artery that extended into the
lower lobe vessels. There was no significant lymphaden-
opathy. She underwent PEA and histological examin-
ation confirmed intimal sarcoma with involvement of
the resection margin. However, after discussion she de-
cided not to have post-operative chemo- or radio-
therapy. She remains free of disease on follow-up CT
scans more than 7 years after her surgery.
Discussion and literature review
PAS is usually asymptomatic until vessel occlusion oc-
curs, and as such patients normally present with signs
and symptoms of advanced disease. These are often sug-
gestive of pulmonary hypertension, heart failure or
thromboembolic disease. Dyspnoea is a universal com-
plaint, although chest pain, oedema and constitutional






- Epirubicin 1 No evidence
of disease
1 Stable disease
- Doxorubicin 1 Progressive disease
- Ifosfamide 1 Stable disease
- Doxorubicin + ifosfamide 1 Stable disease
Palliative (first-line for inoperable and/or metastatic disease)
- Ifosfamide 1 Progressive disease
- Pegylated liposomal doxorubicin
hydrochloride (PLDH)
1 Partial response
- Vincristine + ifosfamide + doxorubicin (VID) 1 Partial response
- Paclitaxel 1 Not evaluable
Palliative (second- and subsequent-line)
- Cisplatin + topotecan 1 Stable disease
- Epirubicin 1 Progressive disease
- Ifosfamide 1 Progressive disease
- Ifosfamide + etoposide 1 Progressive disease
- Paclitaxel 1 Progressive disease
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findings can mimic pulmonary hypertension and in many
cases, inappropriate thrombolytic or anti-coagulant ther-
apy had already been given before a diagnosis of PAS was
considered. Certain features on CT pulmonary angiographyFigure 3 CT images of response to first-line palliative chemotherapy fo
old woman with intimal sarcoma after three cycles of pegylated liposomal do
rhabdomyosarcomatous differentiation after six cycles of vincristine, ifosfamidcould help to differentiate between these two conditions
[13,14]. The role of 18F-fluorodeoxyglucose positron emis-
sion tomography in the diagnosis of PAS is still under in-
vestigation [15,16].
The prognosis for patients with PAS is generally poor,
with a median OS of approximately 17 months as re-
ported here and by others [2,3,8]. Due to the presence of
pulmonary arterial occlusion and the acute symptoms
associated with this, surgical resection is usually the
mainstay of therapy. Surgery for PAS can include pneu-
monectomy, lobectomy, PEA or tumour debulking with
or without pulmonary artery reconstruction, and the
choice of procedure is dependent on factors such as the
tumour location and distal extension. Immediate post-
operative mortality rate has been previously reported to
be around 13-15%, and surgical resection was nearly never
R0 [3,5]. An analysis of combined series by Blackmon
et al. suggested that patients who underwent an attempt
at curative resection have longer OS compared to those
who had incomplete resection (median OS of 36.5 vs
11 months) [2]. Since PAS arises from the vascular endo-
thelium and is often bilateral, the aim of PEA is to remove
the tumour to restore blood flow to affected regions of the
lungs and to relieve the associated pulmonary hyperten-
sion. For this reason, PEA often results in significant
symptom improvement although the resection margins
are rarely clear and therefore the procedure is deemed
non-curative. However, in the unusual event of a unilateral
disease that was diagnosed early, surgical cure by pneu-
monectomy is a possibility provided that the patient hasr inoperable and metastatic pulmonary artery sarcoma. (a) A 57-year-
xorubicin hydrochloride. (b) A 64-year-old man with intimal sarcoma with
e and doxorubicin chemotherapy.
Figure 4 Overall survival of patients with pulmonary artery sarcoma. Kaplan-Meier plots for: (a) all patients in the series (n = 20), (b) patients
who underwent PEA (n = 14) compared to those who did not (n = 6), and (c) patients who received both post-operative chemo- and radio-therapy
(n = 4) compared to those who did not (n = 7 – six had surgery only and one had post-operative chemotherapy alone. Three patients who died
peri-operatively were excluded).
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nately this was not the case for any of our patients in the
series. Even though PEA did not result in a clear survival
benefit, it did provide a significant alleviation of symptoms
(from NYHA class III/IV to I/II). Three of our 14 patients
who underwent PEA died peri-operatively, although two
of them were high-risk surgical candidates following an
emergency transfer from other hospitals due to rapid
cardio-respiratory deterioration.
All of the notable case series published to date have
focused primarily on the surgical aspect of PAS manage-
ment [3,9,10], and the role of post-operative chemo- and
radio-therapy remains unclear. In the combined series
by Blackmon et al., the median survival of those who
had received multimodality treatment was found to be
superior to those who only had single-modality therapy
(median survival of 24.7 and 8.0 months, respectively),
although the latter was defined as either surgery, chemo-
therapy or radiotherapy alone, rather than surgery with
no post-operative treatment [2]. In 2013, Mussot et al.
reported a relatively large surgical series of 31 patients
with PAS [3]. Of these, six received neoadjuvant chemo-
therapy. For adjuvant treatment, 15 received chemother-
apy, two had radiotherapy and one patient received
both. The authors concluded that there appeared to be
no statistical survival benefit in those who received adju-
vant treatment compared to those who did not.A number of peri-operative chemotherapy agents have
been reported in the literature for PAS, including anthra-
cyclines, ifosfamide, gemcitabine, taxanes, platinums and
immunotherapy [2,17-20]. Anthracyclines, either alone or
in combination are the most commonly-used agents, as
with most soft tissue sarcomas. Chemotherapy is normally
given post-operatively, although cases of improved out-
come with neoadjuvant chemotherapy have been de-
scribed – Linden et al. reported a patient whereby tumour
downstaging with neoadjuvant doxorubicin and ifosfamide
allowed a radical pneumonectomy to be performed, result-
ing in a 7-year disease-free survival [7,19]. In our series, a
total of four patients received trimodality treatment with
post-operative chemotherapy and radiotherapy. The me-
dian OS for this group of patients was 24 months com-
pared to 8 months for those who only had surgical
resection (n = 6) or post-operative chemotherapy alone
(n = 1), although this was not statistically significant. All
but one patient had received an anthracycline, and they
tolerated it well without evidence of cardiotoxicity des-
pite symptoms of pulmonary hypertension before PEA.
For patients with inoperable, metastatic or recurrent
PAS, chemotherapy with an anthracycline or its combi-
nations are commonly administered, but others such as
gemcitabine and docetaxel, cisplatin and vinorelbine,
ifosfamide, as well as radiotherapy could also provide rea-
sonable disease control [17,21-24]. In our series, PLDH,
Wong et al. Clinical Sarcoma Research  (2015) 5:3 Page 7 of 8VID, cisplatin and topotecan appeared to have some ac-
tivity in PAS, although disease progression occurred
within months from treatment completion.
Other than chemo- and radio-therapy, a number of re-
ports have found that repeated surgical interventions
could also be associated with prolonged survival in pa-
tients with metastatic PAS [18,25,26]. This is not entirely
surprising, given that surgery for limited metastatic sar-
coma is well established. Indeed, we were able to achieve
some degree of disease control with radiofrequency abla-
tion for our longest surviving patient who developed
lung metastases 7 years after her initial diagnosis.
An inherent shortcoming with a study of such a rare
disease is the small sample size. Another limitation of
our series is the lack of complete data for some patients
that were discharged back to their local hospitals. We do
not have information on any post-operative treatment of
one patient, as well as details of palliative chemo- and/or
radio-therapy of another five patients, although these
were censored accordingly on their last follow-up visits
in the survival analysis.
Is there a role for targeted therapy in PAS? The only tar-
geted agent approved for use in soft tissue sarcoma at
present is the tyrosine kinase inhibitor pazopanib, based
on the results of the PALETTE trial [27]. Its use in PAS
has not been reported – this is likely due to the rarity and
aggressiveness of the disease, and its associated risk of
bleeding and thrombosis that could be viewed as relative
contra-indications for treatment with pazopanib. A fre-
quent observation in the molecular analysis of intimal sar-
coma is gains and amplifications in the chromosomal
region of 12q13-14 and the overexpression of Mdm2, a
negative regulator of p53 [28,29]. Furthermore, amplifica-
tion of genes encoding for the platelet-derived growth fac-
tor receptor α (PDGFA), epidermal growth factor receptor
(EGFR), cyclin-dependent kinase 4 (CDK4) and Gli1
(GLI1) are also commonly found [29-31]. Targeting these
aberrations with small molecule inhibitors might someday
prove beneficial in controlling this devastating disease.
Conclusions
Patients with PAS often have acute symptoms mimicking
pulmonary hypertension, heart failure or thromboembolic
disease. A complete surgical cure is rarely possible as it
usually presents late as bilateral, locally-advanced and/or
metastatic disease. As such PAS carries a dire prognosis,
with a median OS of only 17 months. In our experience,
PEA provides good symptomatic relief to patients and in
some cases offers a chance of long-term survival. Adjuvant
chemo- and radio-therapy may confer a survival benefit
but further studies are needed to confirm this. For patients
with inoperable and/or metastatic PAS, palliative chemo-
and radio-therapy offer a reasonable chance of disease
control and should be considered in all cases.Competing interests
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